CTLA4 and glioma: The main research directions in glioma immunotherapy currently include immune checkpoint inhibitors (such as PD-1/PD-L1 and CTLA-4 inhibitors), CAR-T cell therapy, tumor vaccines, and oncolytic viruses (3).The development of immunotherapy for gliomas has engendered new hope for the treatment of this refractory disease.